Webinaire

Unwinding the patient journey: Simplifying experiences and overcoming patient access barriers

Watch this panel discussion featuring Patrick Collins, MA, Vice President of Corporate Relations at the National Organization for Rare Disorders (NORD); George Eastwood, Board Chair and Interim Executive Director of the Emily Whitehead Foundation; Matthew Lakelin, PhD, Head of Consultancy Services and Co-Founder of TrakCel; Vickie Simpson, RN, Senior Manager of Operations at Cencora; and Dale Hanna, MSc, Director of Cell and Gene Therapy Solutions at Cencora. This panel explores the complexities of the patient journey in accessing cell and gene therapies and how to simplify experiences while overcoming barriers.

Key Insights

In this engaging discussion, the panelists share their insights on the patient journey and the challenges associated with accessing cell and gene therapies:

  • Understanding the patient journey: The panel opens with a recognition of the often-overlooked work performed behind the scenes that impacts patients and providers
  • Educational needs and customization: Our panelists highlight the importance of education in empowering patients and caregivers. The complexity of cell and gene therapies requires tailored support and resources to help patients understand their treatment options and what to expect throughout their journey.
  • Addressing the fear of the unknown: The panel discusses the necessity of educating patients about the nuances of cell and gene therapies, including the importance of post-treatment follow-up and monitoring. 
  • Logistical Challenges and technology solutions: Panelists address the logistical hurdles involved in administering cell and gene therapies, pointing out the importance of managing the supply chain effectively to ensure timely treatment and the need for seamless data exchange among stakeholders.
  • Advocacy and support services: Lastly, the panel emphasizes the role of patient advocacy organizations in bridging gaps in patient support. Panelists advocate for a collaborative approach among stakeholders to ensure that patients receive the necessary information and resources to navigate their treatment journeys successfully.
 

Watch the full recording for a comprehensive understanding of the challenges and solutions related to the patient journey in cell and gene therapies. Fill out the form below to discover how simplification of processes and enhanced patient support can lead to improved access and outcomes for individuals seeking these transformative therapies.

Pardot Form

Building patient trust and empowerment to improve the treatment experience 

Cell and gene therapies have brought transformational advancement to the care of patients with rare diseases, including, in some cases, curative treatments. These therapies are, however, not well understood by patients and their caregivers, and there is also often uncertainty in the physician and payer communities.

Recap: ThinkLive Cell and Gene Therapy Summit 2024

Explore highlights from the Inaugural ThinkLive Cell and Gene Therapy Summit, which unfolded on May 14-15, 2024. Over two days, global and emerging company leaders, providers, and experts converged at this virtual summit to delve into the future of healthcare. The event served as a platform where over 30 speakers across 10 sessions explored six key focus areas at the forefront of healthcare innovation.

Related resources

Nous sommes là pour vous aider

Contactez notre équipe dès aujourd’hui pour en savoir plus sur la façon dont Cencora contribue à façonner l’avenir des soins de santé.

Cencora.com fournit des traductions automatiques pour faciliter la lecture du site Web dans des langues autres que l’anglais. Pour ces traductions, des efforts raisonnables ont été faits pour fournir une traduction précise, cependant, aucune traduction automatique n’est parfaite et n’est pas destinée à remplacer les traducteurs humains. Ces traductions sont fournies à titre de service aux utilisateurs de Cencora.com et sont fournies « en l’état ». Aucune garantie d’aucune sorte, expresse ou implicite, n’est donnée quant à l’exactitude, la fiabilité ou l’exactitude de l’une ou l’autre de ces traductions effectuées de l’anglais vers une autre langue. Certains contenus (tels que les images, les vidéos, Flash, etc.) peuvent ne pas être traduits avec précision en raison des limitations du logiciel de traduction.

Toute divergence ou différence créée lors de la traduction de ce contenu de l’anglais vers une autre langue n’est pas contraignante et n’a aucun effet juridique pour la conformité, l’application ou toute autre fin. Si des erreurs sont identifiées, veuillez nouscontacter. Si vous avez des questions concernant l’exactitude des informations contenues dans ces traductions, veuillez vous référer à la version anglaise de la page.